{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T04:14:46Z","timestamp":1777522486766,"version":"3.51.4"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P41-GM103422"],"award-info":[{"award-number":["P41-GM103422"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P60-DK-20579"],"award-info":[{"award-number":["P60-DK-20579"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["P30-DK-56341"],"award-info":[{"award-number":["P30-DK-56341"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ejphar.2018.12.027","type":"journal-article","created":{"date-parts":[[2018,12,20]],"date-time":"2018-12-20T20:54:07Z","timestamp":1545339247000},"page":"65-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"special_numbering":"C","title":["Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced \u03b1-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy"],"prefix":"10.1016","volume":"845","author":[{"given":"Vijaya B.","family":"Kumar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fong-Fu","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijaya M.","family":"Lakshmi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen N.","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Burke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2018.12.027_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.neulet.2003.10.067","article-title":"Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline","volume":"355","author":"Bar","year":"2004","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2018.12.027_bib2","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1471-4159.2007.04777.x","article-title":"Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil respectively, exert neuroprotective properties in vitro","volume":"103","author":"Bar-Am","year":"2007","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2018.12.027_bib3","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1471-4159.2009.06542.x","article-title":"The neuroprotective mechanism of 1-(R)-aminoindan, the major metabolite of the anti-parkinsonian drug rasagiline","volume":"112","author":"Bar-Am","year":"2010","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2018.12.027_bib4","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature10324","article-title":"Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation","volume":"477","author":"Bartels","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2018.12.027_bib5","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/81834","article-title":"Chronic systemic pesticide exposure reproduces feature of Parkinson's disease","volume":"3","author":"Betarbet","year":"2000","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejphar.2018.12.027_bib6","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1038\/81834","article-title":"Chronic systemic pesticide exposure reproduces features of Parkinson's disease","volume":"3","author":"Betarbet","year":"2000","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ejphar.2018.12.027_bib7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1124\/mol.65.3.655","article-title":"Protein adduct-trapping by hydrazinophthalazine drugs: mechanisms of cytoprotection against acrolein-mediated toxicity","volume":"65","author":"Burcham","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.12.027_bib8","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1124\/mol.105.018168","article-title":"Hydralazine inhibits rapid acrolein-induced protein ologomerization: role of aldehyde scavenging and adduct trapping in cross-link blocking and cytoprotection","volume":"69","author":"Burcham","year":"2006","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.12.027_bib9","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00401-007-0303-9","article-title":"Aggregation of alpha-synuclein by DOPAL, the moamine oxidase metabolite of dopamine","volume":"115","author":"Burke","year":"2008","journal-title":"Acta Neuropathology"},{"key":"10.1016\/j.ejphar.2018.12.027_bib10","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0161-813X(03)00090-1","article-title":"Neurotoxicity of MAO metabolites of catecholamine neurotransmitters: role in neurodegenerative diseases","volume":"25","author":"Burke","year":"2004","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.ejphar.2018.12.027_bib11","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0006-8993(03)03354-7","article-title":"Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson's disease pathogenesis","volume":"989","author":"Burke","year":"2003","journal-title":"Brain Res."},{"key":"10.1016\/j.ejphar.2018.12.027_bib12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/0006-8993(96)00129-1","article-title":"3,4-Dihydroxyphenylglycolaldehyde, the MAO-A metabolite of norepinephrine is selectively toxic to differentiated rat pheochromocytoma cells","volume":"722","author":"Burke","year":"1996","journal-title":"Brain Res."},{"issue":"8","key":"10.1016\/j.ejphar.2018.12.027_bib13","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1021\/tx5002223","article-title":"Benomyl, aldehyde dehydrogenase, DOPAL, and the catecholaldehyde hypothesis for the pathogenesis of Parkinson's disease","volume":"27","author":"Casida","year":"2014","journal-title":"Chem. Res. Toxicol."},{"issue":"1","key":"10.1016\/j.ejphar.2018.12.027_bib14","first-page":"47","article-title":"Metabolites of nicotine in rat brain after peripheral nicotine administration: contine, nornicotine, and norcontine","volume":"25","author":"Crooks","year":"1997","journal-title":"Drug Metab. Dispos."},{"issue":"Suppl 1","key":"10.1016\/j.ejphar.2018.12.027_bib15","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/S1353-8020(13)70019-1","article-title":"Aldehyde dehydrogenase inhibition generates a reactive dopamine metabolite autotoxic to dopamine neurons","volume":"20","author":"Doorn","year":"2014","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.ejphar.2018.12.027_bib16","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1212\/WNL.0000000000000083","article-title":"Aldehyde dehydrogenase variation enhances effect of pesticides associated with Parkinson disease","volume":"82","author":"Fitzmaurice","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ejphar.2018.12.027_bib17","first-page":"1618","article-title":"In vivo measurement of brain monoamine oxidase B occupancy by rasagiline, using (11)C-l-deprenyl and PET","volume":"46","author":"Freedman","year":"2005","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejphar.2018.12.027_bib18","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ijpharm.2012.09.024","article-title":"Controlled release of rasagiline mesylate promotes neuroprotection in a rotenone-induced model of Parkinson disease","volume":"438","author":"Fernandez","year":"2012","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejphar.2018.12.027_bib19","doi-asserted-by":"crossref","first-page":"27660","DOI":"10.1074\/jbc.M115.686584","article-title":"Oligomerization and membrane-binding properties of covalent adducts formed by the interaction of \u03b1-synuclein with the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL)","volume":"290","author":"Follmer","year":"2015","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2018.12.027_bib20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00401-006-0096-2","article-title":"Interaction of alpha-synuclein and dopamine metabolites in pathogenesis of Parkinson's disease: a case for selective vulnerability of substantia nigra","volume":"112","author":"Galvin","year":"2006","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.ejphar.2018.12.027_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1212\/WNL.0000000000002351","article-title":"Prospective study of plasma urate and risk of Parkinson disease in men and women","volume":"86","author":"Gao","year":"2016","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.ejphar.2018.12.027_bib22","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.pharmthera.2014.06.006","article-title":"Catecholamine autotoxicity: implications for pharmacology and therapeutics of Parkinson disease and related disorders","volume":"144","author":"Goldstein","year":"2014","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejphar.2018.12.027_bib23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1468-1331.2010.03246.x","article-title":"Catechols in post-mortem brain of patients with Parkinson disease","volume":"18","author":"Goldstein","year":"2011","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ejphar.2018.12.027_bib24","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1111\/jnc.12345","article-title":"Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease","volume":"126","author":"Goldstein","year":"2013","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.ejphar.2018.12.027_bib25","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/jnc.13042","article-title":"Rotenone inhibits aldehyde dehydrogenase activity: implication for pathogenesis of Parkinson disease","volume":"133","author":"Goldstein","year":"2015","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2018.12.027_bib26","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1124\/jpet.115.230201","article-title":"Comparison of monoamine oxidase inhibitors in decreasing production of the autotoxic dopamine metabolite 3,4-dihydoxyphenylacetaldehyde (DOPAL) in PC-12 cells","volume":"356","author":"Goldstein","year":"2016","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2018.12.027_bib27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.neures.2011.07.003","article-title":"Interplay of salicylaldehyde, lysine, and M2+ ions on alpha-synuclein aggregation: cancellation of aggregation effects and determination of salicylaldehyde neurotoxicity","volume":"71","author":"Ha","year":"2011","journal-title":"Neurosci. Res."},{"key":"10.1016\/j.ejphar.2018.12.027_bib28","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.bbadis.2011.02.013","article-title":"Mitochondrial dysfunction mediated by quinone oxidation products of dopamine: implication in dopamine cytotoxicity and the pathogenesis of Parkinson's disease","volume":"1812","author":"Jana","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejphar.2018.12.027_bib29","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1021\/tx800405v","article-title":"Products of oxidative stress inhibit aldehyde oxidation and reduction pathways in dopamine catabolism yielding elevated levels of a reactive intermediate","volume":"22","author":"Jinsmaa","year":"2009","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.ejphar.2018.12.027_bib30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neulet.2014.03.016","article-title":"Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein","volume":"569","author":"Jinsmaa","year":"2014","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ejphar.2018.12.027_bib31","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.118.248492","article-title":"3,4-Dihydroxyphenylacetaldehyde- (DOPAL)-induced protein modifications and their mitigation by N-acetylcysteine","author":"Jinsmaa","year":"2018","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ejphar.2018.12.027_bib32","first-page":"24","article-title":"Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria","volume":"30","author":"Kristal","year":"2000","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejphar.2018.12.027_bib33","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1002\/(SICI)1097-4547(20000515)60:4<552::AID-JNR14>3.0.CO;2-U","article-title":"Metabolic stress in PC12 cells induces the formation of the endogenous dopaminergic neurotoxin, 3,4-dihydroxyphenylacetaldehyde","volume":"60","author":"Lamensdorf","year":"2000","journal-title":"J. Neurosci. Res."},{"key":"10.1016\/j.ejphar.2018.12.027_bib34","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/ana.20834","article-title":"The Parkinson's complex: parkinsonism is just the tip of the iceberg","volume":"59","author":"Langston","year":"2006","journal-title":"Ann. Neurol."},{"issue":"2","key":"10.1016\/j.ejphar.2018.12.027_bib35","doi-asserted-by":"crossref","first-page":"e9234","DOI":"10.1371\/journal.pone.0009234","article-title":"Modulation of alpha-synuclein aggregation by dopamine analogs","volume":"5","author":"Latawiec","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2018.12.027_bib36","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3858\/emm.2011.43.4.026","article-title":"Dopamine promotes formation and secretion of non-fibrillar alpha-synuclein oligomers","volume":"43","author":"Lee","year":"2011","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejphar.2018.12.027_bib37","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1006\/bioo.1998.1087","article-title":"Synthesis of a biochemically important aldehyde, 3,4-dihydroxyphenylacetaldehyde","volume":"26","author":"Li","year":"1998","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejphar.2018.12.027_bib38","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nrn983","article-title":"Pathogenesis of Parkinson's disease: dopamine, vesicles and alpha-synuclein","volume":"3","author":"Lotharius","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.ejphar.2018.12.027_bib39","doi-asserted-by":"crossref","first-page":"21490","DOI":"10.1074\/jbc.M113.545749","article-title":"Soluble, prefibrillar alpha-synuclein oligomers promote complex I-dependent, Ca2+ induced mitochondrial dysfunction","volume":"289","author":"Luth","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejphar.2018.12.027_bib40","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.brainresrev.2004.12.027","article-title":"Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives","volume":"48","author":"Mandel","year":"2005","journal-title":"Brain Res. Rev."},{"key":"10.1016\/j.ejphar.2018.12.027_bib41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1124\/pr.59.2.1","article-title":"Neurotoxicity and metabolism of the catecholamine derived 3,4-dihydroxyphenylacetaldehyde and 3,4-dihydroxyphenylglycoaldehyde: the role of aldehyde dehydrogenases","volume":"59","author":"Marchitti","year":"2007","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejphar.2018.12.027_bib42","doi-asserted-by":"crossref","first-page":"e350","DOI":"10.1038\/cddis.2012.94","article-title":"Alpha-synuclein: from secretion to dysfunction and death","volume":"3","author":"Marques","year":"2012","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejphar.2018.12.027_bib43","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.parkreldis.2016.08.005","article-title":"Caffeine consumption and the 4-year progression of Parkinson disease","volume":"32","author":"Moccia","year":"2016","journal-title":"Park. Relat. Disord."},{"key":"10.1016\/j.ejphar.2018.12.027_bib44","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.neuron.2009.01.033","article-title":"Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons","volume":"62","author":"Mosharov","year":"2009","journal-title":"Neuron"},{"key":"10.1016\/j.ejphar.2018.12.027_bib45","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/10408440591002183","article-title":"Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effect on human helath","volume":"35","author":"O'Brien","year":"2005","journal-title":"Crit. Rev. Toxicol."},{"key":"10.1016\/j.ejphar.2018.12.027_bib46","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1056\/NEJMoa0809335","article-title":"A double-blind, delayed-start trial of rasagiline in Parkinson's disease","volume":"361","author":"Olanow","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejphar.2018.12.027_bib47","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.expneurol.2007.03.002","article-title":"Anti-fibrillogenic and fibril-destabilizing activity of nicotine in vitro: implications for the prevention and therapeutics of Lewy body diseases","volume":"205","author":"Ono","year":"2007","journal-title":"Exp. Neurol."},{"issue":"12","key":"10.1016\/j.ejphar.2018.12.027_bib48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0015251","article-title":"The neuroxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson's pathogenesis","volume":"5","author":"Panneton","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2018.12.027_bib49","doi-asserted-by":"crossref","first-page":"8210","DOI":"10.1523\/JNEUROSCI.5456-13.2014","article-title":"Is Parkinson's disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum","volume":"34","author":"Pifl","year":"2014","journal-title":"J. Neurosci."},{"key":"10.1016\/j.ejphar.2018.12.027_bib50","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.2174\/092986711797379302","article-title":"Targeting monoamine oxidases with multipotent ligands: an emerging strategy in the search of new drugs against neurodegenerative diseases","volume":"18","author":"Pisani","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2018.12.027_bib51","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.arr.2015.12.002","article-title":"Lysines, Achilles' heel in alpha-synuclein conversion to a deadly neuronal endotoxin","volume":"26","author":"Plotegher","year":"2016","journal-title":"Aging Res. Rev."},{"key":"10.1016\/j.ejphar.2018.12.027_bib52","doi-asserted-by":"crossref","first-page":"40699","DOI":"10.1038\/srep40699","article-title":"DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function","volume":"7","author":"Plotegher","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejphar.2018.12.027_bib53","doi-asserted-by":"crossref","first-page":"S205","DOI":"10.3233\/JAD-2010-091459","article-title":"Effects of caffeine in Parkinson's disease: from neuroprotection to the management of motor and non-motor symptoms","volume":"20","author":"Prediger","year":"2010","journal-title":"J. Alzheimer's Dis."},{"issue":"12","key":"10.1016\/j.ejphar.2018.12.027_bib54","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1002\/mds.21900","article-title":"Nicotine and Parkinson's disease; implications for therapy","volume":"23","author":"Quik","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.ejphar.2018.12.027_bib55","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0304-3940(00)00963-0","article-title":"Enantio-selective occurrence of (S)-tetrahydropapaveroline in human brain","volume":"283","author":"Sango","year":"2000","journal-title":"Neurosci. Lett."},{"issue":"4","key":"10.1016\/j.ejphar.2018.12.027_bib56","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1046\/j.1471-4159.2001.00114.x","article-title":"Synuclein-1 is selectively up-regulated in response to nerve growth factor treatment in PC12 cells","volume":"76","author":"Stefanis","year":"2001","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2018.12.027_bib57","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1021\/bi0121353","article-title":"Vesicle permeabilization by protofibrillar \u03b1-synuclein: comparison of wild type with Parkinson's disease-linked mutants and insights in the mechanism","volume":"41","author":"Volles","year":"2002","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejphar.2018.12.027_bib58","doi-asserted-by":"crossref","first-page":"7812","DOI":"10.1021\/bi0102398","article-title":"Vesicle permeabilization by protofibrillar \u03b1-synuclein: implications for the pathogenesis and treatment of Parkinson's disease","volume":"40","author":"Volles","year":"2001","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejphar.2018.12.027_bib59","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/B978-0-12-386467-3.00007-8","article-title":"Neuroprotective profile of the multitarget drug rasagiline in Parkinson's disease","volume":"100","author":"Weinreb","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.ejphar.2018.12.027_bib60","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.pneurobio.2010.06.008","article-title":"Rasagiline: a novel anti-Parkinsonian monoamine oxidase-B inhibitor with neuroprotective activity","volume":"92","author":"Weinreb","year":"2010","journal-title":"Prog. Neurobiol."},{"issue":"2","key":"10.1016\/j.ejphar.2018.12.027_bib61","doi-asserted-by":"crossref","first-page":"e31522","DOI":"10.1371\/journal.pone.0031522","article-title":"Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson's disease","volume":"7","author":"Wey","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejphar.2018.12.027_bib62","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/sj.bjp.0707167","article-title":"Inflammation as a causative factor in the aetiology of Parkinson's disease","volume":"150","author":"Whitton","year":"2007","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.12.027_bib63","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/nm0602-600","article-title":"Dopamine-dependent neurotoxicity of \u03b1-synuclein: a mechanism for selective neurodegeneration in Parkinson's disease","volume":"8","author":"Xu","year":"2002","journal-title":"Nat. (Med.)"},{"key":"10.1016\/j.ejphar.2018.12.027_bib64","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/sj.bjp.0703826","article-title":"Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B","volume":"132","author":"Youdim","year":"2001","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2018.12.027_bib65","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1749-6632.2001.tb03656.x","article-title":"The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo","volume":"939","author":"Youdim","year":"2001","journal-title":"Ann. N.Y. Acad. Sci."},{"key":"10.1016\/j.ejphar.2018.12.027_bib66","doi-asserted-by":"crossref","first-page":"30424","DOI":"10.1038\/srep30424","article-title":"Aldehyde dehydrogenase 2 is associated with cognitive functions in patients with Parkinson's disease","volume":"6","author":"Yu","year":"2016","journal-title":"Sci. Rep."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918307362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299918307362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,12]],"date-time":"2019-11-12T16:22:55Z","timestamp":1573575775000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299918307362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":66,"alternative-id":["S0014299918307362"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.12.027","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced \u03b1-synuclein aggregation and toxicity: Implication for Parkinson neuroprotective therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2018.12.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}